Why the study?
Does angiotensin II type 1 receptor blockade with losartan reduce atheromatous changes in a genetically hyperlipidaemic mouse model made hypertensive by suprarenal aortic constriction?
Population
Genetically hyperlipidaemic mouse model made hypertensive by suprarenal aortic constriction
Comparison
Angiotensin II type 1 receptor blockade with… vs Unoperated control animals and/or untreated…
Design
Editorial
Authors
Loading...
This editorial highlights findings that mechanical pressure, rather than angiotensin II-mediated effects, is the primary driver of atherogenesis in a hypertensive mouse model, questioning the unique vascular benefits of RAAS inhibition.
Does angiotensin II type 1 receptor blockade with losartan reduce atheromatous changes in a genetically hyperlipidaemic mouse model made hypertensive by suprarenal aortic constriction?
This editorial highlights findings that mechanical pressure, rather than angiotensin II-mediated effects, is the primary driver of atherogenesis in a hypertensive mouse model, questioning the unique vascular benefits of RAAS inhibition.
Graham Macdonald (2006) studied this question.